Introduction to the main functions and clinical application scope of ponatinib

Ponatinib is an oral third-generation multi-target tyrosine kinase inhibitor (TKI). It is mainly used to treat patients with chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). It has significant efficacy especially in cases with drug resistance or containing T315I mutation. Its pharmacological mechanism of action is mainly by inhibiting the tyrosine kinase activity of BCR-ABL fusion protein and blocking abnormal signaling pathways, thereby inhibiting the proliferation and survival of leukemia cells. Compared with early TKI drugs, ponatinib shows greater selectivity and broad spectrum in targeting drug-resistant mutant strains, making it an important treatment option for patients with relapsed drug-resistant leukemia.

In the treatment of chronic myelogenous leukemia, ponatinib is suitable for patients in the chronic phase, accelerated phase and blast phase who are newly treated or who have failed previous TKI treatment. Especially for patients with T315I mutation, due to the limited efficacy of first- and second-generation TKIs such as conventional imatinib, dasatinib or nilotinib, ponatinib can effectively inhibit this mutant BCR-ABL kinase and significantly improve the complete molecular response rate and progression-free survival. In clinical trials, after T315I-positive chronic phase CML patients were treated with ponatinib, the molecular response rate and hematological response rate were significantly better than those in the traditional TKI treatment group.

In acute lymphoblastic leukemia (ALL), ponatinib also shows good therapeutic promise. Patients with Philadelphia chromosome-positive (Ph+) ALL often have the BCR-ABL fusion gene and are less resistant to traditional chemotherapy. By targeting the BCR-ABL kinase, ponatinib can improve the complete response rate in combination chemotherapy regimens and extend patients' progression-free survival and overall survival. Clinical data show that the molecular complete remission rate of Ph+ALL patients using ponatinib combined with chemotherapy is significantly improved. It can also be used as an effective strategy to bridge stem cell transplantation, providing new treatment opportunities for high-risk patients.
In addition to the above indications, ponatinib also shows potential efficacy in certain other hematological tumors, such as some patients with chronic myelogenous leukemia or acute leukemia with different types of BCR-ABL mutations or TKI resistance. It should be noted that cardiovascular events, thrombotic risks, and hematological toxicity may occur during the use of ponatinib. Therefore, during clinical use, the patient's cardiovascular status, blood pressure, and coagulation function need to be strictly assessed, and the dose adjusted according to individualized responses. In general, ponatinib has become an irreplaceable and important drug in the field of leukemia treatment due to its potent inhibitory effect against drug-resistant mutant strains, providing new treatment hope and clinical value for patients with relapsed drug-resistant or mutant leukemia.
Reference link: https://www.drugs.com